Metabolic & Cardiometabolic
PCSK9 inhibitors decreases lipoprotein(a) (~20-30%)
In plain terms: Do PCSK9 inhibitors lower lipoprotein(a), the genetically-driven risk lipid?
Part of: 💊 PCSK9 inhibitors
Yes — evolocumab and alirocumab reduce Lp(a) by roughly 20-30%, a modest but real effect (smaller than for LDL and not enough to fully normalize high Lp(a)).
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Sabatine, Giugliano, Wiviott, Raal, Blom, Robinson, Ballantyne, Somaratne, Legg, Wasserman, Scott, Koren, Stein 2015 · N Engl J Med 372(16):1500-1509 | RCT | supports | low | MAGNITUDE UNVERIFIED. The only lipid outcome in this paper's readable text is LDL cholesterol — 'Patients were followed for a median of 11.1 months with assessment of lipid levels, safety, and (as a prespecified exploratory analysis) adjudicated cardiovascular events', and the sole lipid number reported is the 61% LDL reduction (median 120 -> 48 mg/dL). A case-insensitive search of the full PubMed record returns ZERO occurrences of 'Lp(a)', 'lipoprotein(a)' or 'lipoprotein a'; NEJM 372(16) is paywalled with no PMC deposit, so any Lp(a) result sits in a lipid table this vault cannot read. The previously recorded '~25%' has no provenance in any text the vault holds and has been removed rather than repeated. Stance retained as supports because the direction is not contested by anything readable, but this appraisal is provisional pending full text or the NCT01439880/NCT01854918 results postings. |
| Raal 2015 (RUTHERFORD-2) 2015 · Lancet | RCT | supports | low | Unverified from the text of record. RUTHERFORD-2's reported endpoints are LDL-C only: 'The coprimary endpoints were percentage change from baseline in LDL cholesterol at week 12 and at the mean of weeks 10 and 12, analysed by intention-to-treat.' No lipoprotein(a) result appears anywhere in the available text (0 hits, case-insensitive, full PubMed record), and this source's provenance is abstract-only, so the previously recorded '~22-32%' Lp(a) reduction has no traceable origin. Stance retained pending full text - the trial plausibly reported Lp(a) as a secondary endpoint - but the magnitude is unconfirmed and the appraisal should be retired if paywalled full text or the NCT01763918 results record cannot substantiate it. |
| Dai 2023 · Endokrynol Pol | meta-analysis | supports | moderate | In familial hypercholesterolaemia, alirocumab/evolocumab significantly lowered Lp(a) versus placebo, extending the effect to a genetically high-Lp(a) population. |
| Cao 2019 · Am J Cardiovasc Drugs | meta-analysis | supports | high | Dedicated meta-analysis of 27 RCTs: PCSK9 monoclonal antibodies reduced Lp(a) by a weighted mean of ~21-27% versus placebo, robust across agents and doses. |
| Mulligan 2026 · J Clin Lipidol | meta-analysis | supports | moderate | Head-to-head meta-analysis found evolocumab, alirocumab, inclisiran and newer agents all reduce Lp(a) with no major between-agent differences. |
| Bittner 2020 (ODYSSEY OUTCOMES) venue: J Am Coll Cardiol · J Am Coll Cardiol | RCT | supports | high | ODYSSEY OUTCOMES: alirocumab lowered Lp(a) by median 5.0 mg/dL (~23%); Lp(a) reduction independently predicted fewer major CV events beyond LDL lowering. |
| Gaudet 2017 · Am J Cardiol | RCT | supports | high | Pooled ODYSSEY phase 3 (>4,900 patients): alirocumab lowered Lp(a) ~23-29% sustained over ≥1.5 years, independent of baseline Lp(a) and LDL response. |
| Farmakis 2021 · Am J Cardiovasc Drugs | meta-analysis | supports | high | Pooled 41 RCTs (64,107 patients): PCSK9 inhibitors reduced Lp(a) by 26.7% versus comparators, a robust and consistent effect. |
| Qiao 2026 · Drugs | meta-analysis | supports | high | Umbrella review of meta-analyses confirms PCSK9 inhibitors consistently lower Lp(a) by roughly 20-30% across pooled RCT evidence. |
| O'Donoghue 2019 (FOURIER) venue: Circulation · Circulation | RCT | supports | high | FOURIER: evolocumab cut Lp(a) by median 27%; higher baseline Lp(a) predicted greater CV event reduction, supporting an independent contribution. |
| Zayed 2026 · Diabetes Obes Metab | meta-analysis | mixed | moderate | Network meta-analysis shows PCSK9-directed therapy lowers Lp(a) modestly but far less than dedicated siRNA/ASO agents, so the reduction is real yet comparatively limited. |
| Raal 2014 · J Am Coll Cardiol | RCT | supports | high | Pooled analysis of 4 phase 2 evolocumab trials (1,359 patients): Lp(a) reduced 25-32% dose-dependently — the first systematic demonstration of the effect. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.